Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.62 |
| ▸ | DRD3 | P35462 | 14/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 6/20 | 0.54 |
| ▸ | DRD5 | P21918 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398184 | 0.93 | DRD2 (0.70) | DRD2DRD3ADRB1DRD4DRD5 | |
| SCHEMBL8452211 | 0.85 | DRD2 (0.69) | DRD2DRD3ADRB1DRD4DRD5 | |
| SCHEMBL2131518 | 0.83 | DRD2 (0.67) | DRD2DRD3ADRB1DRD4DRD5 | |
| SCHEMBL30751119 | 0.83 | DRD2 (0.67) | DRD2DRD3ADRB1DRD4DRD5 | |
| SCHEMBL3399574 | 0.81 | DRD2 (0.87) | DRD2DRD3ADRB1DRD4DRD5 | |
| SCHEMBL8318459 | 0.77 | DRD2 (0.68) | DRD2DRD3ADRB1DRD4DRD5 | |
| SCHEMBL13457329 | 0.77 | DRD2 (0.68) | DRD2DRD3ADRB1DRD4DRD5 | |
| SCHEMBL18950672 | 0.77 | DRD2 (0.68) | DRD2DRD3ADRB1DRD4DRD5 | |
| SCHEMBL3399254 | 0.77 | DRD2 (1.00) | DRD2DRD3ADRB1DRD4DRD5 | |
| SCHEMBL22302770 | 0.75 | DRD2 (0.89) | DRD2DRD3DRD4DRD5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156822-B2 | Functionally selective ligands of dopamine D2 receptors | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-05-30 | — | — | US | disclosed |
| WO-2012003418-A2 | FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137679-A1 | Novel Functionally Selective Ligands of Dopamine D2 Receptors | DRD2, AVPR2, NTSR2 | DRD2 1/4885DRD3 12/4885ADRB1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.